Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
420 participants
OBSERVATIONAL
2023-01-01
2027-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME)
NCT06458322
Virtual Ward for Home Dialysis
NCT01912001
Experiences and Health-related Quality of Life of Informal Caregivers of Dialysis Patients
NCT05646615
Preventing Early Dialysis Starts
NCT02183987
A Cluster Randomized Trial to Assess the Impact of Patient and Provider Education on Use of Home Dialysis
NCT02202018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives
1. Determine and compare the trajectory of HRQoL, frailty and caregiver burden during the chronic kidney disease (CKD)-to-dialysis transition. (QUANTI)
2. Examine the experience of participants during their progression from CKD to dialysis. (QUALI)
3. Understand how HRQoL, frailty, and dialysis modality influence patients' and caregivers' experience of transition. (QUANTI+QUALI)
Design and Research Plan TRANSIT-CARE is a 5-year multicenter mixed-methods study of patients with advanced CKD and their caregivers across 12 Canadian centers, with active patient-partner engagement.
QUANTITATIVE Participant will be followed every 3-months (from estimated glomerular filtration rate \[eGFR\] \<12 mL/min/1.73m2) and up to 12-month after dialysis start (4-week, 3-, 6-,12-month).
Target recruitment: 420 patients / 165 caregivers. Dialysis modality will be defined as the chosen modality at baseline visit, and dichotomized as home dialysis (peritoneal or home hemodialysis) and in-center dialysis.
Changes in PROMs and frailty will be assessed using multivariable mixed linear spline regression analysis with each measure used as a continuous variable adjusted for baseline scores, chosen dialysis modality (exposure), dialysis start (time-dependent variable) and prespecified potential confounders.
QUALITATIVE Semi-structured interviews will be conducted with 30 patients and 30 caregivers (from three centers) before and after dialysis initiation.
Thematic analysis will be used to identify patient and caregiver perceptions of home and in-center dialysis, their reactions to dialysis initiation (e.g., feelings of empowerment or loss, life disruption) and perceived burden for caregivers.
Data integration Data from the qualitative and quantitative components will be integrated at time of analysis using tables and joint displays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient - Home Dialysis
Patients transitioning to home dialysis
Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Patient - Facility Hemodialysis
Patients transitioning to facility hemodialysis
Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Caregivers - Home dialysis
Caregivers of patients transitioning to home dialysis
Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Caregivers - Facility Hemodialysis
Caregivers of patients transitioning to facility hemodialysis
Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. estimated glomerular filtration rate (eGFR) \<12 mL/min/1.73m2 103,
3. Have chosen their dialysis modality,
4. Understand English or French.
Exclusion Criteria
2. Planned kidney transplantation \< 6 months,
3. Unable to provide consent due to severe cognitive or psychiatric disease,
4. Previous treatment with dialysis \> 3 months,
5. Life expectancy \< 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
The Kidney Foundation of Canada
OTHER
Ciusss de L'Est de l'Île de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annie-Claire Nadeau-Fredette, MD
Role: PRINCIPAL_INVESTIGATOR
CIUSSS de l'Est-de-l'Ile-de-Montréal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022_2973
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.